Arbor Investment Advisors LLC Takes $1.03 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Arbor Investment Advisors LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,950 shares of the biopharmaceutical company's stock, valued at approximately $1,027,000.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 254 shares during the period. Fifth Third Bancorp increased its stake in Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 261 shares during the period. Private Advisor Group LLC increased its stake in Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock worth $1,191,000 after purchasing an additional 412 shares during the period. Juncture Wealth Strategies LLC increased its stake in Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock worth $690,000 after purchasing an additional 415 shares during the period. Finally, Retirement Systems of Alabama increased its stake in Halozyme Therapeutics by 0.3% during the first quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company's stock worth $6,748,000 after purchasing an additional 436 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares of the company's stock, valued at $4,031,729.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 over the last three months. 2.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

HALO has been the topic of a number of recent research reports. The Goldman Sachs Group boosted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a "neutral" rating in a research note on Monday, July 22nd. Benchmark restated a "buy" rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.44.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $1.21 during trading hours on Monday, hitting $50.46. The stock had a trading volume of 1,167,540 shares, compared to its average volume of 1,278,537. The firm has a market capitalization of $6.42 billion, a PE ratio of 20.85, a PEG ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics, Inc. has a twelve month low of $33.07 and a twelve month high of $65.53. The stock's 50 day moving average is $57.99 and its 200 day moving average is $51.67. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. During the same period last year, the company earned $0.68 earnings per share. The company's revenue for the quarter was up 4.7% on a year-over-year basis. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.